AREG, an epidermal growth factor receptor ligand, is regulated by prolyl-4-hydroxylase domain enzyme 2 (PHD2), a regulator of the stability of HIF-1α that is involved in tumor progression [32] and angiogenesis [33]. The gene discussed is HIF1A; the disease is neoplasm.